Atai Life Sciences: Apeiron, others to extend lock-up for pre-IPO shares 06:59 ATAI Atai Life Sciences announced that Apeiron Investment Group, the family office of its Founder and Chairman, Christian Angermayer, has decided to voluntarily extend its lock-up for all of its pre-IPO common shares for another 24 months, subject to limited exceptions. These shares represent approximately 17.4% of atai's outstanding common shares. In addition, other of atai's largest pre-IPO investors have similarly signed voluntary agreements, extending their respective lock-up restrictions for an additional 12 months, subject to limited exceptions. In the aggregate, these renewed lock-up agreements represent over 30% of atai's outstanding common shares and illustrate the confidence of atai's key shareholders in atai's platform and its potential to address the growing mental health crisis.